Drugs / RADIUM
RADIUM
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT03305224 | Oct 2017 → Oct 2021 | castration-resistant prostate carcinoma, metastatic carcinoma in the bone | Taro Iguchi, MD, PHD | Unknown | No outcome recorded |
| Phase 31 trial · 1 met primary | ||||||
| Phase 3 | NCT02194842 | Oct 2015 → Feb 2024 overdue | prostate cancer | European Organisation for Research and Treatment of Cancer - EORTC | Active not recruiting | Met primary |
News releases announcing trial results or a regulatory action · 7
| Date | Issuer | Release |
|---|---|---|
| 2026-02-26 | Bayer | Results Bayer’s radium-223 dichloride plus enzalutamide demonstrates significant overall survival benefit in the PEACE-3 trial in patients with metastatic castration-resistant prostate cancer with bone metastases bayer.com ↗
Final overall survival (OS) results from the PEACE-3 trial show enzalutamide in combination with radium-223 dichloride reduces the risk of death by 24% versus enzalutamide alone in men with metastatic castration-resistant prostate cancer (mCRPC) and bone metastases |
| 2024-04-03 | Bayer | Results Bayer and Vividion Therapeutics to highlight advancing oncology portfolio at AACR 2024 Annual Meeting bayer.com ↗
Another abstract will highlight the synergistic anti-cancer effects of targeted alpha therapy radium-223 dichloride (Xofigo™) in combination with darolutamide in preclinical prostate cancer models. |
| 2023-04-11 | Bayer | Results Bayer to present latest research across its advancing oncology portfolio at AACR 2023 Annual Meeting bayer.com ↗
Radium-223 demonstrates increased antitumor activity in combination with 177Lu-PSMA-617 in the intratibial LNCaP xenograft model of bone metastatic prostate cancer |
| 2021-04-06 | Bayer | Results Bayer to present new clinical data in indolent non-Hodgkin’s Lymphoma and additional research on its oncology portfolio at AACR Annual Meeting 2021 bayer.com ↗
In addition, preclinical data on the synergistic antitumor effect of radium-223 dichloride and enzalutamide will be presented. |
| 2021-02-08 | Bayer | Results New data presented at 2021 ASCO GU Cancers Symposium add to robustness of the overall survival benefit and favorable safety profile for Nubeqa™ bayer.com ↗
Radium-223 + enzalutamide resulted in significant long-term clinical benefit when compared to enzalutamide alone in mCRPC patients, without compromising safety. |
| 2020-08-27 | Bayer | Regulatory Bayer receives approval for Xofigo® in China bayer.com ↗
The Chinese National Medical Products Administration (NMPA) has approved Xofigo® (radium-223 dichloride) for the treatment of patients with castration-resistant prostate cancer (CRPC), symptomatic bone metastases and no known visceral metastases. |
| 2017-11-30 | Bayer | Results Phase III trial of radium-223 dichloride in combination with abiraterone acetate and prednisone/prednisolone for patients with metastatic castration-resistant prostate cancer unblinded early bayer.com ↗
Bayer today announced that an Independent Data Monitoring Committee (IDMC) has recommended to unblind a Phase III trial of radium-223 dichloride (radium-223) in combination with abiraterone acetate and prednisone/prednisolone in prostate cancer. |
All press releases naming this drug 7 releases
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RADIUM | ChEMBL registry synonym — accepted as the source's own label CHEMBL4300465 ↗ |
| Known as | 223Ra | “Here we publish for the first time fracture rates from an interim safety analysis of the international prospective phase 3 PEACE-3 trial comparing radium-223 (223Ra) combined...” PMID 39827019 ↗ Jan 2025 |
| Known as | Ra-223 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03305224 ↗ |
| Known as | RADIUM RA-223 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4300465 ↗ |
| Known as | Radium-223 | “Here we publish for the first time fracture rates from an interim safety analysis of the international prospective phase 3 PEACE-3 trial comparing radium-223 (223Ra) combined...” PMID 39827019 ↗ Jan 20251“The Study of Combination Therapy With Radium-223 and Enzalutamide in Osaka City University” NCT03305224 ↗ |
| Modality | Small molecule | — CHEMBL4300465 ↗ |
| Route | Intravenous | “Ra-223 (55 kBq/kg i.v.)” NCT03305224 ↗ |